Rosacea : Part II. Topical and systemic therapies in the treatment of rosacea - 17/04/15

Doi : 10.1016/j.jaad.2014.08.027

Aimee M. Two, MD, Wiggin Wu, MD, Richard L. Gallo, MD, PhD, Tissa R. Hata, MD ^⁎
Division of Dermatology, University of California San Diego, San Diego, California

^∗Correspondence to: Tissa R. Hata, MD, Division of Dermatology, University of California San Diego, 8899 University Center Ln, Ste 350, San Diego, CA 92122.

Abstract

Although rosacea's impact on physical health is limited, it has profound effects on a person's psychological well-being. Therefore, treating rosacea can greatly affect a person's quality of life. Patient education regarding trigger avoidance and skin care techniques such as moisturizing and sun protection are important non-pharmacologic first steps in treating rosacea. Pharmacologic interventions range from topical to systemic medications, with the ideal medication choice dependent on the symptoms and severity of each individual patient. Despite this variety of therapeutic options, none of these therapies are completely curative, and therefore further research into the pathophysiology of rosacea is required in order to create more targeted and efficacious treatment options.

Le texte complet de cet article est disponible en PDF.

Key words : alpha-adrenergic receptor agonists, azelaic acid, isotretinoin, metronidazole, rosacea, tetracyclines

Abbreviations used : ETR, FDA, KLK5, MMP, PPR, ROS, TLR2, UV

Plan

Treatment of rosacea

Patient education

Skin care/nonpharmacologic treatments

Pharmacologic treatments

Topical medications

Topical medications for rosacea that have not been approved by the US Food and Drug Administration

Consensus recommendations from the American Acne and Rosacea Society

Emerging therapies

Discussion

	Funding sources: None.
	Dr Two has served as an unpaid consultant for Bayer Pharmaceuticals, Dr Gallo has served as an investigator for Bayer Pharmaceuticals and Galderma, and Dr Hata has served as an investigator for Bayer Pharmaceuticals. Dr Wu has no conflicts of interest to declare.
	Date of release: May 2015
	Expiration date: May 2018